Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Symptoms and General Pathology

Prostatic Neoplasms

Recurrence

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

All Drugs and Chemicals

Hypoglycemic Agents

Lipid Regulating Agents

Androgens

Metformin

Atorvastatin

Biguanides

Anticholesteremic Agents

Hypolipidemic Agents

Antimetabolites

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Enzyme Inhibitors

Atorvastatin 20 mg once daily until progression with one month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.

One placebo tablet (corresponding to atorvastatin) once daily until progression, with one month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.

One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.

Atorvastatin 20 mg once daily until progression.

One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.

Placebo (corresponding to metformin)

One placebo tablet (corresponding to atorvastatin) once daily until progression.

Placebo (corresponding to atorvastatin)

Robert Hamilton, MD, MPH, FRCSC

Neil Fleshner, MD, MPH, FRCSC

This study is a randomized trial examining the administration of a combination of biguanide metformin and atorvastatin ("Lipitor") to men who are experiencing rising prostate-specific antigen (PSA) levels, despite having undergone radical therapy (surgery and/or radiation).

LIpitor and biGuanide to Androgen Delay Trial

A Randomized, Double Blind, Trial of Metformin and Atorvastatin in Delaying Androgen Deprivation Therapy Among Men With Rising PSA Following Radical Prostatectomy or Radiotherapy: The LIGAND (LIpitor and biGuanide to Androgen Delay) Trial

Relationship between body mass index and response to anti-metabolic and anti-cholesterol therapy

Relationship between circulating glycated hemoglobin levels and response to anti-metabolic and anti-cholesterol therapy

Relationship between C-peptide levels and response to anti-metabolic and anti-cholesterol therapy

Relationship between adipokine levels and response to anti-metabolic and anti-cholesterol therapy

Relationship between LDL/HDL cholesterol levels and response to anti-metabolic and anti-cholesterol therapy

Relationship between triglyceride levels and response to anti-metabolic and anti-cholesterol therapy

Assessment of incidence of adverse events from the administration of metformin and atorvastatin to men with prostate cancer.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
LIpitor and biGuanide to Androgen Delay Trial	NCT02497638	Prostate Cancer	Metformin Atorvastatin Placebo (corres... Placebo (corres...	18 Years - 80 Years	University Health Network, Toronto
LIpitor and biGuanide to Androgen Delay Trial	NCT02497638	Prostate Cancer	Metformin Atorvastatin Placebo (corres... Placebo (corres...	18 Years - 80 Years	University Health Network, Toronto

Spots Global Cancer Trial Database for placebo (corresponding to metformin)